Rhythm Pharmaceuticals Inc. ( RYTM ) shares are down during Tuesday’s premarket session following the Monday announcement of topline results from its EMANATE trial. EMANATE was a Phase 3 trial designed to evaluate the efficacy and safety of setmelanotide in patients with rare, genetically driven obesities of the MC4R pathway. EMANATE Trial Misses Primary Endpoints In the EMANATE trial, Rhythm...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

07:13 AM EDT, 03/17/2026 (MT Newswires) -- Nano One Materials ( NNOMF ) on Tuesday provided a progress update on its lithium iron phosphate (LFP) production capacity expansion project at its Candiac facility, which it said will result in an increased capacity of 800 tonnes per annum (tpa). The company said purchase orders for major equipment have been issued and...

March 17 (Reuters) - Victory Capital ( VCTR ) on Tuesday submitted a new bid to acquire rival asset manager Janus Henderson ( JHG ). Under the revised proposal, San Antonio-based Victory is offering $40 in cash and 0.25 of its shares for each Janus share. ...